Shareholder Law Firms Expand Probes of Corcept After FDA CRL for Relacorilant

Overview

• The Schall Law Firm announced a new investigation on January 15 into whether Corcept misled investors about relacorilant, following similar inquiries launched a day earlier by Hagens Berman and Holzer & Holzer.
• The FDA’s Complete Response Letter addressed Corcept’s NDA for relacorilant and stated the agency could not reach a favorable benefit–risk assessment without more evidence of effectiveness.
• Corcept has said the FDA acknowledged GRACE met its primary endpoint and that GRADIENT offered confirmatory data, yet the agency still requested additional proof.
• Corcept’s shares fell about 50% on December 31, 2025, erasing more than $3.6 billion in market value after the CRL disclosure.
• Law firms are urging investors with losses to contact them and, in Hagens Berman’s outreach, potential whistleblowers are being directed to the SEC Whistleblower program.